Global Type 2 Diabetes Therapeutics Market 2015-2019 - New Report Available

Type 2 diabetes is a chronic condition, which arises due to either the inability of the body to produce enough insulin or insulin resistance, or both. Insulin is a peptide hormone produced by the Islets of Langerhans (pancreatic cells). It is produced in an immature form called preproinsulin, which is proteolytically cleaved to obtain proinsulin and then insulin. Type 2 diabetes nearly accounts for 90-95 percent of the total diabetic cases. Type 2 diabetes is usually diagnosed in middle-aged and older people; however, it can occur even during childhood. Type 2 diabetes was also known as adult-onset diabetes or non-insulin-dependent diabetes. Risk factors for type 2 diabetes include high blood pressure, advancing age, overweight, history of gestational diabetes, family history of diabetes, ethnicity, poor nutrition during pregnancy, unhealthy diet, physical inactivity, and IGT.

Full Report Details at
- http://www.fastmr.com/prod/941586_global_type_2_diabetes_therapeutics_market.aspx?afid=301

TechNavio's analysts forecast the Global Type 2 Diabetes Therapeutics market to grow at a CAGR of 7.15 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Type 2 Diabetes Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of following drugs:

* DPP-4 inhibitors
* Biguanides
* Insulins
* GLP-1 receptor agonists
* Thiazolidenediones
* Sulfonulureas
* SGLT-2 inhibitors
* a-Glucosidase inhibitors
* Others (amylinomimetics, bile acid sequestrants, and dopamine receptor agonists)

Further, the territories considered in the report include:

* Americas (US, Brazil, and Mexico)
* 5EU (France, Germany, Italy, Spain, and UK)
* APAC (China, Japan, India, Russia, and other APAC countries)

TechNavio's report, Global Type 2 Diabetes Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Type 2 Diabetes Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

* Americas
* APAC
* EMEA

Key Vendors

* AstraZeneca
* Novartis
* Novo Nordisk

Other Prominent Vendors

* Boehringer Ingelheim
* Bristol-Myers Squibb
* Eli Lilly
* Merck
* Sanofi

Market Driver

* Increased Awareness on Type 2 Diabetes
* For a full, detailed list, view our report

Market Challenge

* Poor Diagnosis Rate
* For a full, detailed list, view our report

Market Trend

* Focus on Emerging Markets
* For a full, detailed list, view our report

Key Questions Answered in this Report

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Type 2 Diabetes Global Clinical Trials Review, H1, 2014
- Type 2 Diabetes - Pipeline Review, H2 2014
- Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth
- Type 1 Diabetes (Juvenile Diabetes) Global Clinical Trials Review, H1, 2014
- Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2014